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Summary
For decades, folic acid has routinely been given to prevent or
treat anaemia in children, pregnant women and people with
sickle cell disease. However, there is no conclusive evidence
that folate deficiency anaemia constitutes a public health
problem in any of these groups. Industrial flour fortification
is recommended and implemented in many countries to
combat neural tube defects. Dietary folates or folic acid can
antagonise the action of antifolate drugs that play a critical
role in the prevention and treatment of malaria. Randomised
trials have shown that folic acid supplementation increases
the rate of treatment failures with sulfadoxine-pyrimetha-
mine. The efficacy of antifolate drugs against Plasmodium is
maximized in the absence of exogenous folic acid, suggesting
that there is no safe minimum dose of ingested folic acid.
We here review the safety and benefits of interventions to
increase folate status in malaria-endemic countries. We con-
clude that formal cost-benefit analyses are required.
Keywords: folic acid, folic acid antagonists, malaria, neural
tube defects, sulfadoxine-pyrimethamine.
Introduction
In developing countries, there are concerns that supplemen-
tation or food fortification with folic acid may reduce the
efficacy of antifolate drugs that play a critical role in the pre-
vention and treatment of malaria. The catalogue of policies
to improve folate status nonetheless continues to grow, and
now includes supplementation, industrial flour fortification,
supplementary feeding and point-of-use fortification (see
Supporting information for current guidelines by the World
Health Organization, WHO).
These concerns add to a debate about flour fortification
with folic acid (e.g., Hubner et al, 2007; Wald & Oakley,
2007). Proponents argue that such fortification should be
mandatory because supplementation and dietary modifica-
tion are largely ineffective in preventing neural tube defects,
and an increased intake of folic acid may reduce rates of car-
diovascular disease and cognitive decline in older age,
whereas opponents contend that health benefits are out-
weighed by theoretical risks of adverse effects, such as cancer
and neuropathies due to masking the diagnosis of vitamin
B12 deficiency.
We aim to review the safety and benefits of interventions
to improve folate status in malaria-endemic countries. First,
we consider folate metabolism, requirements and deficiency
from the perspective of the human host. We then review
folate metabolism and utilisation in Plasmodium parasites,
the mechanism of action of antifolate drugs and current poli-
cies regarding antifolate drugs against malaria. Finally, we
assess the evidence that folic acid interventions and folate
status affect treatment efficacy with these drugs. We focus on
sub-Saharan Africa because the vast burden of malaria occurs
in that region; our conclusions are nonetheless relevant for
malaria-endemic areas elsewhere.
Folate functions and metabolism
Folate is present in cells as dihydrofolate or tetrahydrofolate,
either in reduced form or as their derivatives with a single
carbon unit (Fig 1). The role of reduced tetrahydrofolate, the
active form of folate, is to carry one-carbon units, obtained
from donor molecules, such as the amino acid serine, to
intermediaries in the biosynthesis of a range of compounds
including deoxynucleosides, the molecular building-blocks of
DNA. These intermediaries also transfer methyl (CH3)
groups for binding to DNA (‘methylation’), one of the epige-
netic processes that regulate gene expression. Folate defi-
ciency impairs the division of all cells, but disproportionately
inhibits the development and propagation of rapidly prolifer-
ating cells, such as erythrocyte precursors. As folate depletion
progresses further, it reduces proliferation of cells from other
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haematopoietic lineages and those involved in the immuno-
logical response to infection (Dhur et al, 1991; Koury &
Ponka, 2004). Manifestations of folate deficiency include
neural tube defects, haematological abnormalities and
impaired immunity. In folate deficiency, erythroblasts
undergo increased rates of premature death (ineffective
Fig 1. Folate metabolism in human cells. Folates, metabolites involved in the methionine cycle and methylated end products are indicated in red,
green and yellow, respectively. Methyl donors and methyl receptors are indicated by thick and thin lines, respectively. Reduced tetrahydrofolate,
the active form of folate, serves as a cofactor to carry one-carbon units from donor molecules such as serine to intermediaries in the biosynthesis
of a range of compounds. One such compound is thymidine monophosphate (dTMP), a precursor of thymidine that constitutes one of four
nucleobases in DNA. In the methionine cycle, a methyl group is transferred from 5-methyl-tetrahydrofolate to S-adenosylmethionine (SAM),
which serves as a methyl donor to many acceptor substrates, such as nucleic acids, proteins, lipids and secondary metabolites. Cellular tetrahydro-
folate is obtained from plasma mostly in the form of 5-methyl-tetrahydrofolate, but it can also be derived from folic acid, which is taken up and
converted by the enzyme dihydrofolate reductase via dihydrofolate to tetrahydrofolate. Several metabolic pathways are not shown. For example,
tetrahydrofolate can also react with formic acid to form 10-formyl-tetrahydrofolate, an essential metabolite in the biosynthesis of purines, whilst
homocysteine can also be used for the synthesis of the amino acid cysteine. DHF: dihydrofolate; DHFR: dihydrofolate reductase; dTMP: deox-
ythymidine monophosphate; dUMP: deoxyuridine monophosphate (a deoxynucleotide); (Glu)n: polyglutamate; MS: methionine synthase;
MTHFR: 5, 10-methylene-THF reductase; SAH: S-adenosyl homocysteine; SAM: S-adenosyl methionine; THF: tetrahydrofolate.
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erythropoiesis) as shown by elevated serum concentrations of
bilirubin and lactate dehydrogenase. Although the processes
that lead to neural tube defects are poorly understood, there
is evidence that the effect of folate deficiency is mediated by
a disturbed methylation of DNA, RNA, proteins and lipids
(Beaudin & Stover, 2009).
Humans lack several enzymes required to synthesize folate,
and are entirely dependent on folate from dietary sources.
Dietary folates are mostly conjugated to a polyglutamate
chain. Following ingestion, all are converted to 5-methyl-tet-
rahydrofolate (5-methyl-THF) monoglutamate, mostly in the
mucosa of the small intestine and to some degree in the
liver, before entering into the peripheral circulation (Fig 2).
Absorption of folate polyglutamates is rapid, with blood con-
centrations of 5-methyl-THF increasing within 15–20 min of
ingestion (Pietrzik et al, 2010).
Folic acid (pteroylmonoglutamic acid) is the stable, indus-
trially synthesized form of the vitamin that is used for flour
fortification or supplementation. It does not normally occur
in either dietary sources or the human body. Monogluta-
mates are absorbed more efficiently than dietary folates.
Approximately 90% of a single dose of folate monogluta-
mates is absorbed, regardless of whether the dose is small
(100 lg) or large (15 mg) (Hoffbrand et al, 2011). As with
dietary folates, most folic acid is converted in the small intes-
tine to 5-methyl-THF. With high oral doses of folic acid,
however, this conversion is inefficient, leading to passive dif-
fusion and transitory levels of unmodified folic acid in
plasma (Kelly et al, 1997; Sweeney et al, 2007). The magni-
tude of this effect is dependent on dose and frequency of
intake (Lucock et al, 1989; Powers, 2007), and unaltered folic
acid persists in plasma for 6 h after ingestion of a single dose
(Lucock et al, 1989).
Although folic acid is the first choice for supplementation
or fortification because of its stability and low cost, several
commercially available derivates from natural folates have been
proposed as possible alternatives to folic acid for supplementa-
tion (Pietrzik et al, 2010). 5-methyl-THF is available as its cal-
cium salt, and has comparable bioavailability, physiological
activity and ability to improve folate status at equimolar doses
as folic acid (Pietrzik et al, 2010). Folinic acid (5-formyl-THF;
leucovorin), which has similar vitamin activity, is administered
in conjunction with methotrexate, an antifolate used in the
therapy of cancer and rheumatoid arthritis. When used against
cancer, methotrexate is administered by infusion in high doses
that are life threatening. Folinic acid therapy is started some-
time after initiation of methotrexate therapy to terminate the
toxic effects of methotrexate (‘rescue therapy’). As with folic
acid, folinic acid is metabolized in the intestinal mucosa and
liver to 5-methyl-THF, even at high oral doses (Schalhorn &
K€uhl, 1992; Stern et al, 2000). Not surprisingly, there are con-
cerns that the use of folic acid or folinic acid can lead to
reduced efficacy of methotrexate (e.g., Khanna et al, 2005;
Baggott & Morgan, 2008).
Thus, irrespective of the form or dose of the folate derivate
administered, 5-methyl-THF monoglutamate is by far the pre-
dominant circulating form of exogenous folate available for cel-
lular uptake. It passes cellular membranes either through the
reduced folate carrier or by an endocytotic process mediated by
folate receptors (Kamen et al, 1988) and acts intracellularly as a
methyl donor in the methionine cycle that produces tetrahy-
drofolate and methionine (Fig 1). Intracellular 5-methyl-THF
and many other folate coenzymes are conjugated to a polyglu-
tamate chain, which accounts for their intracellular retention.
In addition, the enzymes involved in folate metabolism have
higher affinity for folate polyglutamates.
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Fig 2. Intestinal absorption of dietary folates, folic acid and 5-methyl-tetrahydrofolic acid. Dietary folates and folic acid at low doses is converted
in the small intestine to 5-methyl-THF. At high oral doses, folic acid enters the circulation through passive diffusion in unmodified form (dotted
line). DHF: dihydrofolate; DHFR: dihydrofolate reductase; Glu: glutamate; (Glu)n: polyglutamate; MTHFR: 5, 10-methylene-THF reductase; THF:
tetrahydrofolate. Adapted from: Clinical Pharmacokinetics, 49, 2010, 535–548, Pietrzik, K., Bailey, L. & Shane, B. Folic acid and L-5-methyltetrahy-
drofolate: comparison of clinical pharmacokinetics and pharmacodynamics. © 2010. With permission of Springer.
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Determinants of folate requirements in Africa
Staple foods commonly consumed in Africa, such as maize,
cassava, sorghum, millet and rice, are poor dietary sources of
folates. Many vegetables are naturally rich in folates. In rural
African populations, however, vegetables are often consumed
in soups, stews or sauces, and losses are typically great
because folates are degraded by extensive cooking or reheat-
ing of foods (Fleming, 1989a).
Pregnant women with malaria are considered to be espe-
cially prone to develop folate deficiency (Fleming, 1989a).
Folate requirements are particularly high in the second and
third trimesters of pregnancy because of the needs imposed
by fetal growth and by accelerated folate breakdown, which
reflects metabolic turnover of folate (WHO/Food and Agri-
culture Organization of the United Nations [FAO], 2004).
Plasma folate concentrations in breast milk are relatively
unaffected by maternal intake, even when the mother is defi-
cient in the vitamin, and maternal supplementation benefits
the mother rather than the infant (Allen, 2012).
Folate requirements are associated with the rate of ery-
thropoiesis. Malaria-induced haemolysis may lead to acceler-
ated or ineffective erythropoiesis and thus increased folate
requirements. Plasmodium infection, however, both during
illness episodes and in symptomless carriers, can also present
with suppressed erythropoiesis (Verhoef et al, 2002), which
would reduce folate requirements. In individuals with high
levels of acquired immunity, the effect of Plasmodium on
haemolysis and thus the increase in folate requirements is
limited. The measurement of folate status in malaria is com-
plicated because Plasmodium parasites cause elevated folate
concentrations in erythrocytes (see below). In addition, folate
concentrations in erythrocytes are 30 times as high as in
plasma, so that even a small degree of (intravascular)
haemolysis can raise plasma folate values and mask cellular
folate deficiency (Antony, 2008).
Chronic haemolysis in individuals with sickle cell disease
results in elevated erythropoiesis rates and is believed to lead
to drastically increased folate turnover and requirements
(Fleming, 1989b). In 2010, 235 681 neonates were born with
sickle cell disease in sub-Saharan Africa (Piel et al, 2013).
About 50–80% of these infants will die before the age of
5 years (WHO, 2010a). Patients suffer from chronic ill health
interspersed with acute anaemic, infarctive and infective
crises. The disease is characterized by erythrocytes with an
abnormal, rigid sickle shape that block small blood vessels,
impair blood flow and reduce erythrocyte survival. The
resulting chronic haemolytic anaemia results in greatly
enhanced erythropoiesis. Even in the steady state, reticulocyte
counts are raised up to 20% (Fleming & De Silva, 2003).
Folate status and effectiveness are affected by a mutation
of the gene encoding for methylenetetrahydrofolate reductase
(MTHFR), the enzyme that regulates conversion of 5,10-
methylene-tetrahydrofolate to 5-methyl-THF (Figs 1,2).
Homozygosity for the 677C?T nucleotide substitution is
associated with a reduction in MTHFR activity, and with
reduced folate concentrations in serum and erythrocytes
(Crider et al, 2011), but its prevalence in African populations
is much lower than among Caucasians (Adjalla et al, 2003;
Pegoraro et al, 2004).
Folate status can also be reduced by the use of drugs that
interfere with host folate metabolism, such as some anti-
malarial drugs; phenobarbital, phenytoin and carbamazepine
used for first-line prevention of epileptic seizures; and
methotrexate. Although widely used in developing countries,
the public health importance of these drugs on folate status
remains largely unknown.
Evidence of folate deficiency
With the exception of women of reproductive age, folate
deficiency is defined by biochemical indicators (i.e., erythro-
cyte folate concentration and/or plasma/serum folate concen-
tration, with cut-off points defining the range below which
homocysteine concentrations become elevated; WHO,
2015a). The public health importance of the impact of apply-
ing these cut-off values is not fully understood (De Benoist,
2008). Elevated concentrations of circulating homocysteine
were once considered as a functional indicator of folate defi-
ciency because of their association with cardiovascular dis-
ease, but the causality of this association is now highly
doubtful (Miller et al, 2010; Clarke et al, 2012).
There are additional reasons why survey reports of folate
deficiency or folate deficiency anaemia should be interpreted
with caution: (i) measurements of folate concentrations in
erythrocytes, serum or plasma are subject to large inter-
laboratory and inter-assay variability (WHO, 2015a); (ii)
even though circulating folate concentrations seem unaffected
by inflammation (Galloway et al, 2000), they can be
increased by Plasmodium infection independently of host
folate status; (iii) interventions that raise folate concentra-
tions in erythrocytes or serum do not necessarily improve
haemoglobin concentrations or reduce the risk of anaemia
(see below), and; (iv) anaemia in the presence of folate defi-
ciency is not necessarily caused by folate deficiency but can
also be due to infections or other micronutrient deficiencies
(Metz, 2008). Thus, at the population level, folate deficiency
can be demonstrated convincingly only through randomised,
placebo-controlled trials showing that folic acid results in
improvements in haemoglobin concentrations or functional
health outcomes.
Prevention of neural tube defects
Trials with folic acid supplementation before conception and
continuing in the first 12 weeks of pregnancy have shown
compelling evidence that the occurrence of neural tube
defects can be reduced by 70% (De Regil et al, 2015). In
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Sub-Saharan Africa, these defects affected 58 000 births, or
21 per 1000 births (2001 data in Christianson et al, 2006),
causing disabilities, often lasting for life, and enormous costs
related to surgeries, physical therapy and rehabilitation.
Anaemia control
Despite programmes for the distribution of folic acid supple-
mentation through antenatal clinics in most countries, there
is no evidence from observational studies that folate defi-
ciency anaemia is a public health problem among infants
and young children in Africa (Metz, 2007) and no evidence
from randomized trials that folic acid supplementation alone
in children or pregnant women leads to reduced anaemia
(Fishman et al, 2000; Lohner et al, 2012). Even in children
with severe anaemia (haemoglobin concentration <50 g/l),
there is no evidence of folate deficiency, and severe anaemia
is not associated with plasma folate concentrations (Calis
et al, 2008).
WHO recommends folic acid supplementation to prevent
anaemia in persons with sickle cell disease (Table SI). Only
one quasi-randomised, placebo-controlled trial has been con-
ducted to assess the effect of folic acid supplementation in
individuals with sickle cell disease, but it failed to demon-
strate that folic acid (5 mg/day) provides benefits to children
as measured by haemoglobin concentrations, or rates of
growth, infection or vaso-occlusive crises (Dixit et al, 2016).
Observational studies also found no evidence that sickle cell
disease was associated with folate status as assessed by folate
concentrations in serum and erythrocytes, and by plasma
homocysteine concentration (Rodriguez-Cortes et al, 1999).
Overall, there is also no evidence to support folic acid inter-
ventions to prevent anaemia in sickle cell disease (Wang,
1999).
Improved pregnancy outcomes
It has been suggested that folate deficiency early in pregnancy
may cause low nucleic acid synthesis and impaired growth of
the placenta, leading to reduced birth weight and preterm
delivery. There is some support from observational studies
and trials that periconceptional supplementation with folic
acid may improve fetal growth and birth weight (Rolschau
et al, 1999; Relton et al, 2005; Timmermans et al, 2009; Fur-
ness et al, 2012), but the evidence remains controversial. A
recent meta-analysis of randomised controlled trials (Lassi
et al, 2013) found no conclusive evidence of benefit of ante-
natal supplementation with folic acid on preterm birth, still-
birth, neonatal death, mean or low birthweight, mean or low
pre-delivery haemoglobin concentration, or pre-delivery
folate concentrations in serum or erythrocytes. A reduction
was found in the relative risk of megaloblastic anaemia, but
the absolute risk reduction was small and findings were
based on 4 trials with severe methodological shortcomings.
The authors found that their results are probably explained
by bias due to non-random allocation, poor concealment
and inadequate blinding, and concluded that there was no
convincing evidence of benefit of folic acid supplementation
during pregnancy on pregnancy outcomes. Similar results
were found in earlier meta-analyses (Mahomed, 1997;
Charles et al, 2005).
Folate and antifolate metabolism in
Plasmodium parasites
Because Plasmodium does not incorporate exogenous thy-
mine or thymidine, the thymidylate required for DNA syn-
thesis must be synthesized de novo through the folate cycle.
Protozoa and bacteria generally synthesize folates de novo
from guanosine-triphosphate (a precursor of dihydropteroate
diphosphate), para-aminobenzoic acid (pABA) and glutamate
(Fig 3). This synthetic pathway has long been a target for
drugs used against rapidly reproducing cells such as Plasmod-
ium parasites and microbial pathogens.
Sulfonamides and sulfones, such as sulfadoxine, sul-
famethoxazole and dapsone, are structural analogues to
pABA, and act as competitive inhibitors of dihydropteroate
synthetase (DHPS), an enzyme that acts by converting pABA
to DHPS. These drugs have selective antiparasitic or antibac-
terial activity because DHPS is lacking in humans (Nzila
et al, 2005; Nzila, 2006).
By contrast, diaminopyrimidines, such as pyrimethamine,
proguanil and trimethoprim, competitively inhibit dihydrofo-
late reductase (DHFR), thus blocking the conversion of dihy-
drofolate to tetrahydrofolate, as well as the conversion of
folic acid to dihydrofolate (Fig 3). Diaminopyrimidines act
selectively because they bind much more strongly to bacterial
and parasitic DHFR than the corresponding human enzyme
(Stokstad & Jukes, 1987). In addition, selectivity of DHFR
inhibitors may be based on human-parasite differences in the
regulation and expression of DHFR (Zhang & Rathod, 2002).
Sulfonamides and diaminopyrimidines have a greater
effect when given combined than the sum of their effects
when given separately (Gregson & Plowe, 2005); the reason
for this synergy may be that they block two successive steps
in the same metabolic pathway.
In Plasmodium spp., blocking of folate synthesis by antifo-
lates results in decreased concentrations of tetrahydrofolate,
decreased conversion of serine to glycine, reduced synthesis
of thymidylate, and ultimately to decreased production of
parasite DNA (Gregson & Plowe, 2005). Rapidly dividing
cells, such as Plasmodium parasites, have a high demand for
nucleotide precursors for DNA synthesis, and thus are partic-
ularly sensitive to antifolates. DHPS and DHFR inhibitors act
against all human malaria parasites, but P. falciparum is
inherently more sensitive than P. vivax, P. malariae and
P. ovale (Gregson & Plowe, 2005).
In addition to endogenous production of folate, however,
many strains of Plasmodium parasites are also capable of uti-
lizing exogenous folic acid or folinic acid through specialized
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Fig 3. Folate metabolism in erythrocytic stages of Plasmodium parasites. Methyl donors and methyl receptors are indicated by thick and thin
lines, respectively. In the endogenous pathway, Plasmodium can synthesize dihydrofolate and tetrahydrofolate de novo from dihydropteroate,
pABA and glutamate moieties. Antifolate drugs (e.g. sulfadoxine, pyrimethamine) act by competitive binding to enzymes involved in this syn-
thetic pathway. Thus DHPS is competitively inhibited by sulfadoxine and dapsone, whereas DHFR is competitively inhibited by pyrimethamine,
proguanil and trimethoprim (red arrows). This antifolate activity results in inhibition of folate synthesis and, ultimately, reduced synthesis of
thymidylate and parasite DNA. Ingested folic acid enters the circulation when ingested in high doses (dashed blue line). The parasite can access
circulating folic acid and convert it through DHFR to dihydrofolate and tetrahydrofolate. By utilising the exogenous folic acid as a source of
folates, the parasite can bypass the inhibition of the endogenous pathway and thus antagonise the activity of antifolate drugs. In theory, 5-
methyl-THF is a methyl donor in the methionine cycle (lower cycle, with metabolites in green), resulting in the production of tetrahydrofolate
and methionine (blue dotted lines). Recent evidence from an in vitro study suggests, however, that this pathway is not effectively utilised in Plas-
modium, either because 5-methyl-THF monoglutamate from the erythrocytic pool cannot cross the membranes of the parasitophorous vacuole
and the parasite (blue dotted line, with question mark) or because the parasite does not need methionine, because it derives this amino acid pre-
cursor of S-adenosylmethionine from haemoglobin degradation or human plasma (Nduati et al, 2008). This evidence suggests that oral 5-methyl-
THF may act as a source of folates in humans without antagonising the in vitro activity of antifolate drugs against P. falciparum (Nduati et al,
2008; Nzila et al, 2014). DHF: dihydrofolate; DHFR: dihydrofolate reductase; DHPS: dihydropteroate synthase; dTMP: deoxythymidine
monophosphate; dUMP: deoxyuridine monophosphate (a deoxynucleotide); pABA: para-aminobenzoic acid: SAM: S-adenosyl methionine; THF:
tetrahydrofolate.
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protein carriers across the erythrocyte membrane and across
the membranes of the parasitophorous vacuole and the para-
site (Krungkrai et al, 1990; Wang, 1999; Nzila et al, 2005).
To avoid antagonizing the action of sulfadoxine, in vitro tests
for sulfadoxine resistance require that human serum, which
is needed to support parasite growth in culture, is depleted
of residual folic acid and folinic acid (Chulay et al, 1984;
Geary et al, 1985; Wang et al, 2007). Folic acid added to an
in vitro P. falciparum culture competitively antagonizes the
inhibitory action of pyrimethamine in a linear dose-relation-
ship (Wang, 1999). Given the propensity of ingested folic
acid to result in the formation of unmodified folic acid in
plasma, these studies suggest that interventions with folic
acid or folinic acid can reduce the antimalarial activity of
antifolate drugs and thus their efficacy in a dose-dependent
manner.
Erythrocytes and liver cells accumulate 5-methyl-THF in
the polyglutamate form, but it is doubtful that this store can
be utilised by intracellular stages of P. falciparum, because (i)
this pool may be insufficient to sustain intracellular develop-
ment; (ii) the parasite probably lacks glutamyl hydrolase, the
enzyme that is required to remove the polyglutamate moi-
eties; and (iii) antifolates would not have antimalarial activity
if a source of folate is present that would bypass the action
of these drugs (Ferone, 1977; Krungkrai et al, 1990).
There is some evidence that the parasite can utilise exoge-
nous 5-methyl-THF to derive methionine by de novo synthe-
sis (Krungkrai et al, 1990; Nzila et al, 2005). If this pathway
were used to produce THF, the parasite could theoretically
bypass the inhibition of folate synthesis that is induced by
antifolate drugs. An in vitro study recently showed, however,
that even at supra-physiological concentrations, 5-methyl-
THF hardly antagonised the activity of pyrimethamine and
chlorcycloguanil against P. falciparum (Nduati et al, 2008).
This finding indicates that either 5-methyl-THF is not trans-
ported into the parasite cell or that 5-methyl-THF is present
intracellularly but the de novo methionine pathway is not
effectively utilised, perhaps because the parasite can use hae-
moglobin degradation or human plasma as an alternative
source of methionine (Nduati et al, 2008).
Antifolate resistance in P. falciparum is due primarily to
mutations in dhps and dhfr (Gregson & Plowe, 2005), result-
ing in altered structure and reduced drug affinity of DHPS
and DHFR. This suggests that the interference of ingested
folic acid with antifolate drug action is probably most pro-
nounced in situations with high levels of antifolate resistance.
In addition, such reduced antifolate efficacy is likely to
depend on the dose and duration of the folic acid interven-
tion, and on host folate status.
Policies regarding antifolate drugs against
malaria
Given the enormous burden of malaria, and the important
role that antifolate drugs continue to play in its prevention,
even small reductions in efficacy of these drugs are likely to
have major public health repercussions. In 2015, there were
an estimated 438 000 malaria deaths and 214 million epi-
sodes of malaria worldwide; of these, 395 000 deaths (90%)
and 188 million cases (88%) occurred in WHO’s African
Region (i.e. sub-Saharan Africa except Sudan and Somalia)
(WHO, 2015b). Approximately 74% of African malaria
deaths occurred in children aged below 5 years (WHO,
2015b). Low birth weight associated with malaria in preg-
nancy may result in 100,000 infant deaths in Africa annually
(Guyatt & Snow, 2004). In areas of high and moderate trans-
mission, P. falciparum infection in pregnant women often
occurs without symptoms but accounts for a substantial pro-
portion of cases of maternal anaemia, low birth weight and
infant deaths (Desai et al, 2007).
Sulfadoxine-pyrimethamine (Fansidar) is recommended by
WHO for pregnant women and young children for chemo-
prevention in areas with a high burden of malaria (WHO,
2010b, 2014) (Table I). Chemoprevention comprises the
repeated administration at curative doses of a slowly elimi-
nated antimalarial drug, which results in periods in which
subsequent new infections are inhibited by persistent but
declining concentrations of the drug (post-treatment prophy-
lactic effect). Thus pregnant women should receive therapeu-
tic courses of antimalarial drugs on at least three occasions
(regardless of the presence or absence of infection) adminis-
tered at antenatal clinic visits at least 1 month apart, and
starting after quickening (WHO, 2014). This strategy exploits
the opportunity provided by a high proportion of pregnant
women attending antenatal clinics at least once during preg-
nancy, and many attending at least twice. It substantially
reduces the prevalence of maternal anaemia, placental para-
sitaemia and the occurrence of low birth weight, whilst no
marked adverse events to sulfaxodine-pyrimethamine in
either mother or infant have been detected (WHO, 2014).
Sulfaxodine-pyrimethamine is the only drug recommended
for this purpose because of its safety in pregnancy, efficacy,
and because it can be delivered as a single dose under super-
vision to ensure adherence. By 2014, it had been adopted as
a national policy in 36 countries with a high burden of
malaria in Sub-Saharan Africa, Laos, Papua New Guinea and
the Philippines (WHO, 2015b). In those countries for which
consistent data were available, coverage varied considerably
between countries, but it was estimated that half of women
attending antenatal clinics received at least one therapeutic
dose (WHO, 2015b).
Intermittent preventive treatment with sulfadoxine-pyri-
methamine has been shown to substantially reduce malaria
rates both in infants and older preschool children (Mere-
mikwu et al, 2008; Wilson, 2011). It was endorsed as a policy
in infants only through its co-administration with second
and third doses of diphtheria-tetanus-pertussis vaccine
(DTP2, DTP3) and measles immunization at 10, 14 weeks
and 9 months of age, respectively (WHO, 2010b). In 2012,
the WHO recommended that children aged 3–59 months in
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areas of highly seasonal malaria transmission across the Sahel
sub-region should receive therapeutic courses of sulfadoxine-
pyrimethamine plus amodiaquine at monthly intervals,
beginning at the start of the transmission season, to a maxi-
mum of four doses during the malaria transmission season,
and with delivery overseen by community volunteers (‘sea-
sonal malaria chemoprevention’) (WHO, 2012). By 2015,
only one country (Chad) had adopted a national policy of
intermittent preventive treatment for infants, whilst eight
countries (Chad, Congo, The Gambia, Guinea, Mali, Niger,
Senegal and Togo) have national programmes for seasonal
malaria chemoprevention. Coverage may accelerate with the
increasing availability of financial support (WHO, 2015b).
Sulfadoxine-pyrimethamine is also used in combination
with artesunate for first-line treatment of uncomplicated
malaria in Afghanistan, Azerbaijan, India, Iran, Pakistan,
Saudi-Arabia, Somalia, Sudan and Yemen (WHO, 2015b).
Although first-line therapy containing an artemisinin deriva-
tive is now the standard for falciparum malaria worldwide, a
small but important proportion of children in sub-Saharan
Africa continue to be treated with sulfaxodine-pyrimetha-
mine alone (WHO, 2015b).
Proguanil is used prophylactically (in combination with
chloroquine) in pregnant women at risk of P. falciparum
(Botswana, South Africa and Swaziland) and as second-line
treatment for P. falciparum (French Guyana). It is also used
with atovaquone (Malarone) both for treatment and preven-
tion of malaria among tourists, but a donation programme
initiated in 1996 to make this combination available to ende-
mic countries was discontinued because of cost considera-
tions (Oyediran et al, 2002). Chlorproguanil combined with
dapsone (Lapdap) was also used to treat malaria but this was
discontinued following reports that it leads to reduced
haematocrit values and severe anaemia in persons with glu-
cose-6-phosphate dehydrogenase (G6PD) deficiency, an
inherited human enzyme defect that is common in African
populations (Luzzatto, 2010).
Malaria is the most common precipitating cause of crises
in sickle cell disease in endemic countries. To avoid such
crises, national guidelines in many countries recommend that
Table I. Recommendations by the World Health Organization for preventive therapies against malaria with antifolate drugs.
Target group Policy name Definition Intervention Setting Reference
Pregnant
women
Intermediate Preventive
Treatment for pregnant
women (IPTp)
To control the effects
of Plasmodium infection
on the pregnant woman
and her fetus
At least two and possibly
three* therapeutic (single)
doses of sulfadoxine-
pyrimethamine, to be
delivered after quickening.
Sulfadoxine-pyrimethamine
should not be given more
frequently than monthly,
and should not be
administered concurrently
with cotrimoxazole
Areas of medium-high
transmission (stable)
WHO
(2014)
Infants Intermediate Preventive
Treatment for
infants (IPTi)
To reduce the malaria
burden of targeted
children
Therapeutic (single) doses of
sulfadoxine-pyrimethamine,
to be delivered through
immunization services –
usually at 10, 14 weeks and
approximately 9 months of
age, to infants at risk of
malaria
Areas of moderate to high
transmission in Sub-
Saharan Africa
WHO
(2010b)
Children aged
3–59 months
Seasonal malaria
chemoprevention,
previously referred to as
Intermittent Preventive
Treatment in
children (IPTc)
To prevent malaria in
targeted children
A treatment course of
sulfadoxine-pyrimethamine
(single dose) plus
amodiaquine (once daily
for 3 days), at monthly
intervals, beginning at the
start of the transmission
season, to a maximum of
four doses during the
malaria transmission season
Areas of highly seasonal
malaria transmission across
the Sahel sub-region
WHO
(2012)
*The World Health Organization recommends a schedule of four visits to antenatal clinics, with three visits after quickening (the moment that a
pregnant woman first perceives or feels motion of the fetus in the uterus, usually at a gestational age of 18–20 weeks in primigravidae, or
15–17 weeks in multiparae; Levene et al, 2000).
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people with sickle cell anaemia receive life-long prophylaxis
with antimalarial medicines, which often include the antifo-
lates proguanil, pyrimethamine or a combination thereof
(Oniyangi & Omari, 2006).
Lastly, cotrimoxazole, a combination of the antifolate
drugs trimethoprim and sulfamethoxazole, can be used to treat
malaria, but it is also indicated as primary prophylaxis
against human immunodeficiency virus (HIV)-related infec-
tions in children and adults with HIV/acquired immunodefi-
ciency syndrome, including pregnant women after the first
trimester; and in any infants born to HIV/infected mothers
(WHO, 2013).
Increased folate intake and malaria
The Tolerable Upper Intake Limit (i.e., the highest average
daily intake level of a nutrient that is unlikely to pose a
potential risk of adverse effects to all apparently healthy indi-
viduals in an age- and sex-specific group) (UL) for folic acid
was set to avoid neuropathy due to vitamin B12 deficiency in
non-target groups (WHO/FAO, 2004), and does not take
into account adverse effects due to its interference with
antifolate drugs. Antagonistic effects with antifolate drugs
may occur because of transient but recurrent elevation of cir-
culating levels of 5-methyl-THF or unmetabolized folic acid
following ingestion of folic acid, or because of high folate
status either through long-term interventions or a diet rich
in natural folates.
Supplementation
At least four randomized controlled trials in humans have
shown that supplementation with folic acid can reduce the
therapeutic efficacy of sulfadoxine-pyrimethamine (Table II).
In Gambian children treated for uncomplicated malaria,
adjunct supplementation with folic acid for 28 days resulted
in an increased frequency of treatment failure with sulfadox-
ine-pyrimethamine. The folic acid dose in this trial was very
high (5–10 mg/day dependent on body weight, as compared
to an intake of 48–180 lg, dependent on age, being sufficient
Table II. Effect of folic acid on therapeutic efficacy of sulfadoxine-pyrimethamine against malaria; summary of randomized controlled trials.
Country Study population Comparison* Key finding(s) Reference
The Gambia Children aged 6 months to
9 years with uncomplicated
Plasmodium falciparum
malaria, treated with iron
Daily folic acid (5, 75 and
10 mg for children
weighing <15, 15–20 and
>20 kg, respectively) versus
placebo
Folic acid increased the risk of
parasitological failure at day 7
(11% vs. 5%; P = 025) and day
28 (30% vs. 15%; P = 004) after
the start of treatment
Boele van Hensbroek et al
(1995)
Kenya Patients of all ages with
uncomplicated
P. falciparum malaria and
mild-moderate anaemia,
treated with iron
Daily folic acid (25 and
5 mg for those aged <2
and ≥2 years, respectively)
versus placebo
Folic acid increased the risk of
parasitological failure
(P < 00001). No evident effect on
risk of clinical failure
Carter et al (2005)
Zambia Children aged 6–119 months
with uncomplicated
P. falciparum malaria and
haematocrit 9–21%, treated
with iron
Daily folic acid (1 mg)
versus placebo
Folic acid increased the risk of
parasitological failure at days 3
(P = 001), 7 (P = 012), and 14
(P = 044) after the start of
treatment
Mulenga et al (2006)
Kenya Pregnant women with
gestational age 17–34 weeks
with Plasmodium infection
and haemoglobin
concentration >70 g/l
Daily folic acid (either 5 or
04 mg) versus placebo
Compared to placebo, folic acid
(5 mg) increased parasitological
failure risk at day 14 (27% vs.
14%; adjusted HR, 985% CI: 219,
109–440†; P = 0005).
Corresponding values for folic acid
(04 mg): 145%; adjusted HR
107, 048–237. No evident effect
on haemoglobin concentrations
Ouma et al (2006); Van Eijk
et al (2008)
The Gambia Primigravidae with
gestational age >15 weeks
and haemoglobin
concentration >70 g/l
receiving iron
Daily folic acid (15, 10 and
05 mg for those with
haemoglobin concentration
70–90, 90–110 and ≥110
g/l) versus placebo
Folic acid had no evident effect on
parasitological failure, but
marginally improved haemoglobin
concentration (14 g/l, 95%
CI 01–27 g/l)
Mbaye et al (2006)
CI, confidence interval; HR, Hazard ratio.
*All study participants received treatment with sulfadoxine/pyrimethamine.
†To account for multiple comparisons and the interim analysis, Ouma et al (2006) reported 987% CIs instead of conventional 95% CIs.
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to meet the dietary needs of 975% of children in the studied
age range of 6 months to 9 years; WHO/FAO, 2004). Even in
this group of children with elevated risk of folate deficiency
due to malaria-induced haemolysis, folic acid did not improve
haematological recovery (haemoglobin concentrations, mean
cell volume or mean corpuscular haemoglobin concentration)
even though it led to a marked increase in erythrocyte folate
concentrations (Boele van Hensbroek et al, 1995).
In Kenyan patients treated for falciparum malaria with
sulfadoxine-pyrimethamine, daily supplementation with folic
acid (25 or 5 mg for those aged <2 and ≥2 years, respec-
tively) reduced the time to treatment failure as assessed by
parasitological examination of blood slides collected at vari-
ous points of follow-up (Carter et al, 2005). There was no
evidence of an effect on recovery from anaemia.
Folic acid (1 mg/day) increased the risk of parasitological
treatment failure with sulfadoxine-pyrimethamine in Zam-
bian children even though it led to a marginal improvement
of haematocrit [12%, 95% confidence interval (CI) 02–
22%] by day 14 of follow-up. In this study, folic acid had
no evident effect on the risk of parasitaemia in children trea-
ted with atovaquone-proguanil (Mulenga et al, 2006).
In Kenyan pregnant women with Plasmodium infection,
daily supplementation with 5 mg folic acid doubled the risk of
treatment failure with sulfadoxine-pyrimethamine at 14 days
(Ouma et al, 2006). A lower dose of folic acid (04 mg/day)
resulted in a marginal and statistically non-significant risk
increase (145% vs. 139%; P = 08). The absence of a statisti-
cally significant effect has been interpreted as evidence that this
lower dose is safe; however, the upper limit of the reported
confidence interval of the hazard ratio (107, 987% CI: 048–
237; adjusted for differences in baseline factors, and CI taking
into account multiple comparisons and interim analysis), only
excludes a 24-fold increase in the hazard of treatment failure.
Again, there were no evident effects of folic acid on haemoglo-
bin concentration at the end of the study.
In a trial among pregnant women in The Gambia (Mbaye
et al, 2006), folic acid was supplemented at a daily dose of
05–15 mg, depending on initial haemoglobin concentration
[its distribution (mean, range: 97, 61–158 g/l) suggests that
most women in this trial received a daily dose of 05 or
10 mg]. There was no evidence that folic acid increased
treatment failure risk at 14 days after administration of sulfa-
doxine-pyrimethamine (57% vs. 49% in the placebo group;
risk difference: 07%, 95% CI: 22% to 37%). Caution
should be exercised in extrapolating this finding over geo-
graphical areas or time. At the time that this trial was under-
taken (2002–2003), P. falciparum was still highly susceptible
to sulfadoxine-pyrimethamine in West Africa, which is
reflected in the low risk of treatment failures reported. Folic
acid had a statistically significant but negligible effect on hae-
moglobin concentration (14 g/l, 95% CI: 01–27 g/l).
In a small placebo-controlled trial among US soldiers in
Vietnam treated with pyrimethamine, sulfisoxazole and
chloroquine for P. falciparum malaria, folic acid (5 mg) or
folinic acid (5 mg for 5 days) improved haematocrit values,
leucocyte counts and platelet counts without evidently delay-
ing the time to clearance of parasitaemia (Tong et al, 1970).
These findings are difficult to interpret, however, because all
patients received a therapeutic regimen of chloroquine,
which may have precluded detection of possible interference
of the folate derivates with antifolates.
In a randomized trial among Tanzanian children aged 1–
35 months (Sazawal et al, 2006), daily supplementation with
folic acid (50 lg) and iron increased rates of hospital admis-
sion and all-cause mortality (combined endpoint) by 12%
(95% CI: 2–23%). Because sulfadoxine-pyrimethamine was
used for first-line malaria treatment, it cannot be excluded
that the adverse events were attributable at least in part to
supplemental folic acid.
Folate status
In Malawian children aged 05–12 years, high blood folate
concentrations were prognostic for treatment failure with
sulfadoxine-pyrimethamine (odds ratio: 150, 95% CI: 108–
198; adjusted for other risk factors) (Dzinjalamala et al,
2005). Unfortunately, the cut-off value to define high blood
folate concentrations was not specified in this study. In a
randomized trial among Kenyan pregnant women (Van Eijk
et al, 2008), high folate status was defined as plasma folate
concentrations >154 lg/l. Such high status occurred in 3%
of women at baseline, and was associated with a marked risk
of treatment failure with sulfadoxine-pyrimethamine (hazard
ratio: 408, 95% CI: 167–1000) (Van Eijk et al, 2008).
Evidence from in vitro studies, animal studies and obser-
vational studies in humans suggest that increasing folate sta-
tus and intake is associated with increased risk and
progression of malaria independent of effects on antimalarial
drug efficacy (reviewed by Nzila et al, 2016). This effect of
intake may be mediated by an increase in folate species other
than 5-methyl-THF. Alternatively, and similarly to what has
been shown with iron supplementation (Clark et al, 2014),
folate can lead to a transient increase in reticulocyte num-
bers, which are favoured by Plasmodium species for invasion
and reproduction.
Flour fortification
Internationally recommended levels of folic acid fortification
vary by country between 1 and 5 mg/kg flour, depending on
per capita flour consumption, and were set at the highest
possible levels without exceeding the UL (WHO/FAO/United
Nations Children’s Fund [UNICEF]/Global Alliance for
Improved Nutrition [GAIN]/Micronutrient Initiative [MI]/
Flour Fortification Initiative [FFI], 2009; Berry et al, 2010).
In many countries, implementation of these guidelines can
be expected to result in a median daily intake of at least
200 lg in women of reproductive age (H. Verhoef, unpub-
lished data, available upon request).
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In the USA, the level of folic acid fortification was set at
14 mg/kg cereal grain product, which was expected to raise
the average daily intake of folic acid in women of reproduc-
tive age by 100 lg (Eichholzer et al, 2006). Data collected
before and after the start of mandatory fortification (1998)
indicate, however, that (i) typical intakes of folic acid from
fortified foods were more than twice the level originally pre-
dicted (Choumenkovitch et al, 2002; Quinlivan & Gregory,
2003; Bailey, 2004); (ii) the median serum folate concentra-
tion in the US population more than doubled from 55 lg/l
(12 nmol/l) in the pre-fortification period (1988–94) to
131 lg/l (297 nmol/l) in the early post-fortification period
(1999–2000) (Berry et al, 2010; Yetley & Johnson, 2011); (iii)
concentrations of unmodified folic acid in circulation
increased (Kalmbach et al, 2008). Thus the experience with
fortification in the USA strongly suggests that internationally
recommended fortification levels will result in increased con-
centrations of 5-methyl-THF and chronic presence in circula-
tion of unmetabolized folic acid in a substantial proportion
of the population.
The WHO recommendation that erythrocyte folate con-
centrations in women of reproductive age should exceed
400 lg/l (906 nmol/l) to achieve the greatest reduction of
neural tube defects (WHO, 2015a) is based on findings that
also suggested a corresponding threshold for serum folate
concentration of 7 lg/l (159 nmol/l) (Daly et al, 1995).
Thus, given the variability in serum folate concentrations, it
seems likely that flour fortification actually attained or tar-
geted to prevention of neural tube defects will result in a
substantial proportion of African women transiently or
chronically exceeding the threshold serum folate concentra-
tion of >154 lg/l that has been associated with treatment
failure for sulfadoxine-pyrimethamine (Van Eijk et al, 2008).
Discussion and conclusions
In contradiction to the long-held assumptions that have dri-
ven past recommendations on folate administration, there is
no compelling evidence that folate deficiency anaemia consti-
tutes a public health problem in children, pregnant women
attending antenatal clinics, or individuals with sickle cell dis-
ease. By itself, this lack of evidence raises questions about
recommendations to use folic acid in supplements, supple-
mentary foods and point-of-use fortificants that are provided
to these groups. In addition, there is substantial evidence that
adherence to current guidelines about folic acid supplemen-
tation may cause failure of chemoprevention against malaria.
The efficacy of antifolate drugs against Plasmodium is maxi-
mized in the absence of exogenous folic acid, so that there
may not be a minimum safe dose.
Reports that high circulating folate concentrations predict
treatment failure with sulfadoxine-pyrimethamine adminis-
tered to pregnant women, and may even cause malaria with-
out mediation by antimalarial drugs, may have far-reaching
implications for the safety of current flour fortification
recommendations. Monitoring of flour fortification pro-
grammes has been recommended but will not be helpful:
even a modest increase in malaria rates is likely to go unde-
tected given the spatial and temporal variability in malaria
incidence in endemic areas, and attribution will be impossi-
ble in uncontrolled conditions.
In its recent guidelines, the WHO recommends that sup-
plements with iron and folic acid in malaria-endemic areas
should be the provided in conjunction with adequate public
health measures to prevent, diagnose and treat malaria. Even
with the progress that has been made in controlling malaria
in the last decade, however, the efficacy and coverage of such
measures is inadequate in most, if not all, settings because:
(i) in areas of stable malaria, and under trial conditions,
insecticide-impregnated mosquito nets can reduce overall
child mortality by one-sixth and it can reduce the incidence
of uncomplicated malarial episodes by half (Lengeler, 2004);
(ii) only two-thirds of children aged below 5 years in sub-
Saharan Africa sleep under insecticide-treated nets, whilst
vector resistance to pyrethroids – the only class of insecti-
cides available for mosquito net impregnation – is spreading
and intensifying to an extent that they may be approaching
the end of their useful lifespan; (iii) indoor residual spraying
protects only 6% of the population in all of sub-Saharan
Africa, with coverage declining in recent years (WHO,
2015b); and (iv) in 2014, 84% of children aged <5 years with
malaria did not receive appropriate drugs, primarily because
a high proportion of children with fever are not taken for
care, or use the informal private sector (WHO, 2015b).
Formal risk-benefit analysis is needed to establish to what
extent the prevention of neural tube defects resulting from
flour fortification with folic acid outweighs the risk of
malaria in the overall population.
Further studies are also needed to establish to what extent
5-methyl-THF is a safe, affordable and practicable alternative
to folic acid in malaria-endemic areas (Nzila et al, 2014).
The evidence suggesting that oral 5-methyl-THF may act as a
source of folates in humans without antagonising the activity
of antifolate drugs against P. falciparum (Nduati et al, 2008)
is promising but it is derived from a single in vitro study
with only two P. falciparum laboratory strains.
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